CHENGDU, China, Sept. 24 /PRNewswire-Asia-FirstCall/ -- -- Q4 FY 2009 Revenues increased 43.2% to $13.3 Million, Net Income increased 41.8% to $2.2 Million with diluted EPS of $0.08 -- FY 2009 Revenues increased 28.2% to $42.9 Million and Net Income Increased 32.4% to $7.9 Million vs. FY08 with diluted EPS of $0.32 -- FY 2009 Cash flow from operations increased 124.8% to $8.3 Million -- June 30, 2009 Cash and equivalents of $12.4 million, working capital of $19.3 million and current ration of 5.4 to 1 -- Completed construction and received GMP approval for its new manufacturing facility -- Company successfully launched 9 products during FY09 -- Reaffirms Fiscal 2010 Guidance: Revenues Expected to Exceed $59 Million with a Net Income of at Least $10.5 million
Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009.
Fourth Quarter Ending June 30, 2009 Financial Results
Fourth quarter 2009 revenues were $13.3 million, representing a 43.2% increase from $9.3 million recorded in the fourth quarter of fiscal 2008. The increase was driven by enhanced marketing and advertising programs supporting a broader product portfolio and improvements in the Company's sales channels which led to increased market penetration. Revenues in the fourth quarter generated by the top three selling products, Ginkgo Mihuan Oral Liquid, Arpu Shuangxin Oral Liquid, and Azithromycin Dispersible Tablets, were collectively $7.8 million and represented approximately 58.6% of total revenues for the quarter. During the fourth quarter of fiscal 2008 sales of top three products were approximately $5.9 million which represented 63.4% of total revenue.
Cost of sales in the fourth quarter 2009 increased 41.6% to $6.8 million, from $4.8 million in the fourth quarter of 2008. Gross profit in the fourth quarter 2009 was $6.5 million, a 44.9% increase from $4.5 million in the fourth quarter of 2008.
Gross margins were 48.7% in the fourth quarter of 2009, compared to 48.9% in the third quarter of 2009 and 48.2% in the fourth quarter of 2008.
Operating expenses were $3.7 million and operating income was $2.8 million in the fourth quarter of 2009, representing a 45.2% increase from $1.9 million reported in the fourth quarter of 2008.
Net income for the quarter was $2.2 million, up 41.8% from net income of $1.5 million in the same period a year ago. Income taxes were approximately $0.5 million representing an effective tax rate of 18.5%.
Fully diluted earnings per share were $0.08 for the last quarter of 2009, compared to fully diluted earnings per share of $0.05 in the fourth quarter of 2008.
Tianyin incurred a one time impairment loss on intangible assets of $0.4 million related to Huganning Tablets, Qianbai Biyan Tablets and Xiaoyan Lidan Tablets. Without this charge net income would have been $2.6 million with diluted EPS of $0.10 based on 26.3 million shares.
Dr. Guoqing Jiang, Chief Executive Officer of Tianyin, commented, "We are very pleased with our financial results. Several factors contributed to our strong performance for the fiscal year as growth accelerated in the fourth quarter. These included our ability to achieve SFDA approvals and launch several new products, an expanded marketing strategy focused on branding key products, and our ability to gain market share by leveraging a large internal sales team with key distributors. We met a significant milestone by completing the construction of our new production facility which greatly improves our capacity to support growth during fiscal 2010 and beyond. While the past year was challenging for the global marketplace, we took decisive corporate actions which included issuing a cash dividend and buying back stock to reward our loyal shareholders."
Year Ending June 30, 2009 Financial Results
For the fiscal year ended June 30, 2009, revenues increased 28.2% to $42.9 million from $33.5 million reported for the prior year period. Expanded sales efforts helped create strong demand for the Company's branded and generic drugs including the introduction of 9 new drugs. Ginkgo Mihuan, one of Tianyin's flagship products, contributed approximately $11.6 million or 27.1% to total revenues for the fiscal year 2009, representing 28% year-over-year growth. Revenues generated from the Arpu Shuangxin Oral Liquid were $10.4 million, or 24.2% of total revenues, a 54.3% increase from fiscal 2008. Tianyin's top 5 selling products generated revenue of $29.3 million and represented 68.3% of total revenue.
Cost of goods sold for fiscal year 2009 was approximately $21.5 million, yielding a gross profit of $21.4 million and gross margins of 49.8%, compared to $14.7 million in gross profit and a gross margin of 43.8% for fiscal year of 2008. The 600 basis point improvement in gross margins was primarily attributable to the growth in revenue, product mix optimization, enhanced cost control and focus on higher margin products in the Company's portfolio such as Ginkgo Mihuan Oral Liquid and Arpu Shuangxin Oral Liquid.
Operating expenses for fiscal year 2009 were $11.7 million, up 64.5% compared to the same period in 2008. Selling, general and administration expenses for the period increased to approximately $7.8 million from $4.7 million. The increase was primarily due to enhanced marketing efforts including increased sales payrolls and direct marketing expense.
Operating income totaled approximately $9.7 million, a 28.4% increase from the $7.6 million reported for fiscal year 2008. Operating margins were 22.7% and 22.6% for the fiscal year 2009 and 2008, respectively.
For fiscal 2009, net income was approximately $7.9 million, a 32.4% increase from $6.0 million recorded for fiscal 2008 and surpassed previously announced guidance by approximately 5.3%. Diluted earnings per share were $0.32, compared to $0.31 in the same period 2008, based on 24.8 million and 19.1 million shares for 2009 and 2008, respectively. The increase in the diluted shares was related to preferred stock which carries a fixed conversion price of $1.60.
The provision for income taxes was $1.6 million and $1.2 million for fiscal 2009 and 2008 with an effective tax rate was 17.2% and 17.1%, respectively.
"China's healthcare reform is being implemented to provide basic medical care for its 1.3 billion citizens by 2020 with approximately $126 billion being allocated during the next three years alone. This initiative is well underway as evidenced by the build-out of new Clinics and the publishing of the formal EDL. This creates significant growth opportunities for Chinese pharmaceutical companies like Tianyin which possess a diversified product portfolio and extensive sales and distribution channels. We currently have 17 products in our R&D pipeline which address wide range of chronic and critical conditions. We expect to receive additional SFDA approvals during fiscal 2010 which will further diversify our branded product base with high margin revenue potential while enabling us to further differentiate our company from our competitors. We will leverage the new production capacity to continue the growth momentum in fiscal 2010 and beyond," concluded Dr. Jiang.
Balance Sheet and Cash Flow
The Company had a current ratio of 5.4 to 1 and $12.4 million in cash and cash equivalents on June 30, 2009. Stockholders' equity was $40.9 million, with working capital of $19.3 million$ and total liabilities of $4.4 million. Days Sales Outstanding for fiscal 2009 were 48 days compared to 49 days for 2008. For the fiscal year of 2009, the Company generated $8.3 million in cash from operations versus $3.7 million for the same period in 2008.
Significant Business Developments -- Tianyin engaged a major advertising firm to commence a marketing initiative for its Xuelian Chongcao Oral Liquid product that will include prominent, prime-time advertisements on China Central Television (CCTV), China's most famous television station, which is viewed by 98% of households throughout China. Xuelian Chongcao Oral Liquid is an Over-The-Counter TCM drug that effectively replenishes kidney functionality and also improves overall energy. -- Tianyin completed construction of its new production facility in Chengdu which recently received Good Manufacturing Practices Certificate for pharmaceutical products from the State Food and Drug Administration ("SFDA") in China. Construction was delayed due to the earthquake in Sichuan which occurred on May 12, 2008. The new production facility is expected to triple the production capacity of solid dosage drugs, such as Azithromycin Dispersible Tablets, Mycophenolate Mofetil Capsules, and Dantong Capsules, and will be able to support approximately $100 million in annual revenues assuming the current product mix. The Company expects to commence production by October, 2009. -- Tianyin further expanded its product portfolio during fiscal 2009 which now totals 39 drugs. The Company received 10 new production approvals from the Chinese SFDA for drugs which address multiple medical conditions and will be produced in the new facility to drive incremental growth. The company has 17 different drugs currently moving through the approval process. -- Tianyin had four products included in China's Essential Drug List (EDL) released by the Chinese government on August 18, 2009. Azithromycin Dispersible Tablets, Simvastatin Tablets, Hugan Tablets and Xiao Yan Li Dan Capsules and Tablets are all generic. The inclusion will significantly increase revenues generated by these products while the gross margin will be lower due to pricing control. -- Tianyin declared a quarterly cash dividend of $0.025 with the second dividend being paid in September to common stock shareholders of record as of July 31, 2009. In addition, the Company announced and executed a buyback program during fiscal 2009.
Fiscal 2010 Guidance
For fiscal year 2010 which ends June 30, 2010, Tianyin forecasts that revenues will exceed $59 million with net income at least $10.5 million, representing approximately 37.5% and 32.9% growth compared to fiscal 2009. Management anticipates that approximately $7 million, or 12% of total revenues will emanate from products which were launched during fiscal 2009, while sales of the Company's flagship product, Ginkgo Mihuan, will grow by approximately 80% to $20 million for the year. Net income forecasted does not include non- cash expenses associated with stock compensation plans or future interest expense. This guidance does not include any contribution from potential future acquisitions. Manage will continue to evaluate and update guidance if and when its appropriate.
The Company will host a conference call to discuss the 2009 annual financial results on Thursday, September 24, 2009 at 10:30 a.m. EDT. Interested participants should call 877-941-2068 within the United States, or US +1-480-629-9712 if calling internationally. The conference ID is 4161412. It is advisable to dial in approximately 5-10 minutes prior to 10:30 a.m. EDT. If you are unable to participate in the call at the scheduled time, a playback will be available through October 8, 2009. Please call 800-406-7325 from within the United States, or US +1-303-590-3030 internationally. Please use pass code 4161412 for the replay.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts during the presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO in China Tel: +86-158-2122-5642 Email: Allen.firstname.lastname@example.org Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: email@example.com Web: http://www.hcinternational.net -- FINANCIAL TABLES FOLLOW -- Consolidated Balance Sheet June 30, June 30, 2009 2008 Assets Current assets: Cash and cash equivalents $12,352,223 $12,057,150 Accounts receivable, net of allowance for doubtful accounts of $171,947 and $90,064 at June 30, 2009 and 2008, respectively 5,620,519 4,460,406 Inventory 3,808,289 3,555,691 Advance payments 1,188,115 -- Other receivables 601,912 371,815 Other current assets 81,277 247,139 Total current assets 23,652,335 20,692,201 Property and equipment, net 9,642,526 5,758,966 Intangibles, net 12,037,483 10,307,754 Total assets $45,332,344 $36,758,921 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $1,392,639 $1,337,682 Short-term bank loans 1,399,075 1,393,345 VAT taxes payable 458,930 277,090 Income taxes payable 490,514 341,214 Other taxes payable 11,890 39,939 Dividends payable 325,417 378,545 Other current liabilities 307,934 142,733 Total current liabilities 4,386,399 3,910,548 Total liabilities 4,386,399 3,910,548 Stockholders' equity: Common stock, $0.001 par value, 50,000,000 shares authorized, 17,908,912 and 14,738,450 shares issued and outstanding at June 30, 2009 and 2008, respectively 17,909 14,739 Series A convertible preferred stock, $0.001 par value, 7,146,500 and 9,384,375 shares issued and outstanding at June 30, 2009 and 2008, respectively 7,147 9,384 Additional paid-in capital 19,694,514 18,002,439 Statutory reserve 2,299,807 1,380,806 Treasury stock (111,587) -- Retained earnings 16,486,775 10,963,131 Accumulated other comprehensive income 2,551,380 2,477,874 Total stockholders' equity 40,945,945 32,848,373 Total liabilities and stockholders' equity $45,322,344 $36,758,921
Consolidated Statements of Operations and Comprehensive Income
For the Years Ended June 30, 2009 2008 Sales $42,894,355 $33,459,609 Cost of sales 21,516,065 18,802,225 Gross profit 21,378,290 14,657,384 Operating expenses Selling expenses 7,825,939 4,725,480 General and administrative expenses 3,491,804 2,132,438 Research and development 343,952 230,745 Total operating expenses 11,661,695 7,088,663 Income from operations 9,716,595 7,568,721 Other income (expenses): Interest income 357,343 -- Interest expense (95,880) (368,113) Impairment loss on intangible assets (431,344) -- Total other income (expenses) (169,881) (368,113) Income before provision for income tax 9,546,714 7,200,608 Provision for income tax 1,639,104 1,229,300 Net income 7,907,610 5,971,308 Other comprehensive income Foreign currency translation adjustment 73,506 2,044,766 Comprehensive income $7,981,116 $8,016,074 Basic earnings per share $0.41 $0.38 Diluted earnings per share $0.32 $0.31 Weighted average number of common shares outstanding: Basic 15,937,411 14,511,717 Diluted 24,805,281 19,127,853
Consolidated Statements of Cash Flows
For the Years Ended June 30, 2009 2008 Cash flows from operating activities: Net Income $7,907,610 $5,971,308 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 676,605 372,612 Loss on intangible assets 431,344 -- Provision for bad debts 81,512 51,995 Stock based compensation 249,026 68,000 Changes in current assets and current liabilities: Accounts receivable (1,223,282) (994,310) Inventory (237,975) (1,400,366) Other receivables (253,595) (209,556) Other current assets 190,890 (246,952) Accounts payable and accrued expenses 49,867 31,336 VAT taxes payable 180,701 41,771 Income tax payable 147,897 2,228 Other taxes payable (28,213) 13,521 Other current liabilities 164,611 7,330 Total adjustments 429,388 (2,262,391) Net cash provided by operating activities 8,336,998 3,708,917 Cash flows from investing activities: Additions to property and equipment (58,014) (211,065) Additions to construction in progress (4,179,902) (757,295) Additions to intangible assets-drug (2,417,250) (3,702,484) Advance payments for intangible assets-drug (1,188,115) -- Net cash used in investing activities (7,843,281) (4,670,844) Cash flows from financing activities: Issuance of preferred stock -- 13,248,054 Dividends paid (73,944) (83,206) Repayment of short-term bank loans -- (826,140) Treasury stock (111,587) -- Repayment of shareholder loans -- (146,143) Repayment of long-term bank loans -- (119,667) Net cash provided by (used in) financing activities (185,531) 12,072,898 Effect of foreign currency translation on cash (13,113) 321,789 Net increase in cash and cash equivalents 295,073 11,432,760 Cash and cash equivalents at beginning of year 12,057,150 624,390 Cash and cash equivalents at end of year $12,352,223 $12,057,150
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2009 PR Newswire.
All rights reserved